199 related articles for article (PubMed ID: 35135596)
1. Up-regulation of MTHFD2 is associated with clinicopathological characteristics and poor survival in ovarian cancer, possibly by regulating MOB1A signaling.
Cui X; Su H; Yang J; Wu X; Huo K; Jing X; Zhang S
J Ovarian Res; 2022 Feb; 15(1):23. PubMed ID: 35135596
[TBL] [Abstract][Full Text] [Related]
2. MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion.
Lin H; Huang B; Wang H; Liu X; Hong Y; Qiu S; Zheng J
Cell Physiol Biochem; 2018; 51(2):991-1000. PubMed ID: 30466107
[TBL] [Abstract][Full Text] [Related]
3. MTHFD2 promotes ovarian cancer growth and metastasis via activation of the STAT3 signaling pathway.
Li Q; Yang F; Shi X; Bian S; Shen F; Wu Y; Zhu C; Fu F; Wang J; Zhou J; Chen Y
FEBS Open Bio; 2021 Oct; 11(10):2845-2857. PubMed ID: 34231329
[TBL] [Abstract][Full Text] [Related]
4. Interference with MTHFD2 induces ferroptosis in ovarian cancer cells through ERK signaling to suppress tumor malignant progression.
Mo X; Liu Q; Liang K; Song Y
J Bioenerg Biomembr; 2024 Jun; 56(3):333-345. PubMed ID: 38488992
[TBL] [Abstract][Full Text] [Related]
5. MTHFD2 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating AKT/GSK-3β/β-catenin signalling.
Shi Y; Xu Y; Yao J; Yan C; Su H; Zhang X; Chen E; Ying K
J Cell Mol Med; 2021 Jul; 25(14):7013-7027. PubMed ID: 34121323
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of MTHFD2 inhibits NSCLC progression by suppressing cycle-related genes.
Yu C; Yang L; Cai M; Zhou F; Xiao S; Li Y; Wan T; Cheng D; Wang L; Zhao C; Huang X
J Cell Mol Med; 2020 Jan; 24(2):1568-1577. PubMed ID: 31778025
[TBL] [Abstract][Full Text] [Related]
7. p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage.
Li G; Wu J; Li L; Jiang P
Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34244426
[TBL] [Abstract][Full Text] [Related]
8. Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer.
Achreja A; Yu T; Mittal A; Choppara S; Animasahun O; Nenwani M; Wuchu F; Meurs N; Mohan A; Jeon JH; Sarangi I; Jayaraman A; Owen S; Kulkarni R; Cusato M; Weinberg F; Kweon HK; Subramanian C; Wicha MS; Merajver SD; Nagrath S; Cho KR; DiFeo A; Lu X; Nagrath D
Nat Metab; 2022 Sep; 4(9):1119-1137. PubMed ID: 36131208
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of circ-MTHFD2 in diagnosis, pathological staging and prognosis of NSCLC.
Geng QQ; Wu QF; Zhang Y; Zhang GJ; Fu JK; Chen NZ
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9473-9479. PubMed ID: 33015789
[TBL] [Abstract][Full Text] [Related]
10. Non-metabolic function of MTHFD2 activates CDK2 in bladder cancer.
Liu X; Liu S; Piao C; Zhang Z; Zhang X; Jiang Y; Kong C
Cancer Sci; 2021 Dec; 112(12):4909-4919. PubMed ID: 34632667
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial targeting of MTHFD2 and PAICS in purine synthesis as a novel therapeutic strategy.
Cheung CHY; Hsu CL; Tsuei CY; Kuo TT; Huang CT; Hsu WM; Chung YH; Wu HY; Hsu CC; Huang HC; Juan HF
Cell Death Dis; 2019 Oct; 10(11):786. PubMed ID: 31624245
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications.
Ju HQ; Lu YX; Chen DL; Zuo ZX; Liu ZX; Wu QN; Mo HY; Wang ZX; Wang DS; Pu HY; Zeng ZL; Li B; Xie D; Huang P; Hung MC; Chiao PJ; Xu RH
J Natl Cancer Inst; 2019 Jun; 111(6):584-596. PubMed ID: 30534944
[TBL] [Abstract][Full Text] [Related]
13. High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion.
Lehtinen L; Ketola K; Mäkelä R; Mpindi JP; Viitala M; Kallioniemi O; Iljin K
Oncotarget; 2013 Jan; 4(1):48-63. PubMed ID: 23295955
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial MTHFD isozymes display distinct expression, regulation, and association with cancer.
Nilsson R; Nicolaidou V; Koufaris C
Gene; 2019 Oct; 716():144032. PubMed ID: 31377316
[TBL] [Abstract][Full Text] [Related]
15. High Expression of Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) in Esophageal Squamous Cell Carcinoma and its Clinical Prognostic Significance.
He H; Li PC; Jia W; Hu B; Ji CS
Med Sci Monit; 2020 Feb; 26():e920259. PubMed ID: 32088725
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-33a-5p suppresses colorectal cancer cell growth by inhibiting MTHFD2.
Yan Y; Zhang D; Lei T; Zhao C; Han J; Cui J; Wang Y
Clin Exp Pharmacol Physiol; 2019 Oct; 46(10):928-936. PubMed ID: 31209892
[TBL] [Abstract][Full Text] [Related]
17. MTHFD2-mediated redox homeostasis promotes gastric cancer progression under hypoxic conditions.
Mo HY; Wang RB; Ma MY; Zhang Y; Li XY; Wen WR; Han Y; Tian T
Redox Rep; 2024 Dec; 29(1):2345455. PubMed ID: 38723197
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin inhibits SIRT3-deacetylation MTHFD2 to disturb cellular redox balance in colorectal cancer cell.
Wan X; Wang C; Huang Z; Zhou D; Xiang S; Qi Q; Chen X; Arbely E; Liu CY; Du P; Yu W
Cell Death Dis; 2020 Aug; 11(8):649. PubMed ID: 32811824
[TBL] [Abstract][Full Text] [Related]
19. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.
Shang M; Yang H; Yang R; Chen T; Fu Y; Li Y; Fang X; Zhang K; Zhang J; Li H; Cao X; Gu J; Xiao J; Zhang Q; Liu X; Yu Q; Wang T
Nat Commun; 2021 Mar; 12(1):1940. PubMed ID: 33782411
[TBL] [Abstract][Full Text] [Related]
20. Glioma cells require one-carbon metabolism to survive glutamine starvation.
Tanaka K; Sasayama T; Nagashima H; Irino Y; Takahashi M; Izumi Y; Uno T; Satoh N; Kitta A; Kyotani K; Fujita Y; Hashiguchi M; Nakai T; Kohta M; Uozumi Y; Shinohara M; Hosoda K; Bamba T; Kohmura E
Acta Neuropathol Commun; 2021 Jan; 9(1):16. PubMed ID: 33468252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
